Effects of sodium nitrite and catechol, 3-methoxycatechol, or butylated hydroxyanisole in combination in a rat multiorgan carcinogenesis model.
Effects of simultaneous treatment with NaNO2 and butylated hydroxyanisole, catechol, or 3-methoxycatechol were examined in a rat multiorgan carcinogenesis model. Groups of 15 animals were given a single i.p. injection of 100 mg/kg of body weight diethylnitrosamine, 4 i.p. injections of 20 mg/kg of body weight N-methylnitrosourea, 4 s.c. injections of 40 mg/kg of body weight dimethylhydrazine, p.o. treatment with 0.05% N-butyl-N-(4-hydroxybutyl)nitrosamine in the drinking water for the first 2 weeks and p.o. treatment with 0.1% 2,2'-dihydroxy-di-n-propylnitrosamine in the drinking water for the next 2 weeks of the initial 4-week initiation period. Starting 3 days after the completion of these carcinogen treatments, animals were given diets containing 2% butylated hydroxyanisole, 0.8% catechol, 2% 3-methoxycatechol, or basal diet either alone or in combination with 0.3% sodium nitrite until week 28, when complete autopsy was performed. Histological examination showed that NaNO2 strongly enhanced development of forestomach lesions but inhibited that of glandular stomach lesions in rats simultaneously given catechol or 3-methoxycatechol with or without prior carcinogen exposure. 3-Methoxycatechol promoted esophageal carcinogenesis either with or without NaNO2, but promoting effects of catechol were evident only in the presence of NaNO2. In addition, treatment with NaNO2 after carcinogen exposure enhanced forestomach carcinogenesis. These results indicate that NaNO2 can modify phenolic antioxidant-induced cell proliferation and/or carcinogenesis, particularly in the upper digestive tract.
Hirose
M
M
First Department of Pathology, Nagoya City University Medical School, Japan.
Tanaka
H
H
Takahashi
S
S
Futakuchi
M
M
Fukushima
S
S
Ito
N
N
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology* / Q000633:toxicity; D001835:Body Weight / Q000187:drug effects; D002083:Butylated Hydroxyanisole / Q000494:pharmacology; D002278:Carcinoma in Situ / Q000139:chemically induced; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced; D002396:Catechols / Q000494:pharmacology; D003043:Cocarcinogenesis; D004127:Dimethylhydrazines; D004195:Disease Models, Animal; D004347:Drug Interactions; D004435:Eating / Q000187:drug effects; D004848:Epithelium / Q000187:drug effects / Q000473:pathology; D006965:Hyperplasia / Q000139:chemically induced; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008297:Male; D008770:Methylnitrosourea; D009374:Neoplasms, Experimental / Q000139:chemically induced*; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D011916:Rats, Inbred F344; D012977:Sodium Nitrite / Q000494:pharmacology* / Q000633:toxicity; D013270:Stomach / Q000187:drug effects / Q000473:pathology; D013274:Stomach Neoplasms / Q000139:chemically induced*
D000975:Antioxidants; D002396:Catechols; D004127:Dimethylhydrazines; D002083:Butylated Hydroxyanisole; D008770:Methylnitrosourea; C066344:3-methoxycatechol; C034221:catechol; D012977:Sodium Nitrite